OTC · Biotechnology

HOOKIPA Pharma Inc. (HOOK) Stock

$1.15 +0.00% OTC: HOOK Healthcare

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer.

Valuation

MetricValue
Price$1.15
Market Cap$14.40M
P/E Ratio-0.71
P/B Ratio0.51
P/S Ratio1.64
EPS (TTM)$-1.09
52-Week High$1.55
52-Week Low$0.81
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-54.85%
ROA-32.66%
ROCE-62.07%
Gross Margin100.00%
Operating Margin-278.95%
Net Margin-195.62%
Debt/Equity0.02
Current Ratio3.93

Annual Financials (USD)

Metric20212022202320242025
Revenue$18.0M$14.0M$20.0M$44.0M$10.0M
Operating Profit$-82.0M$-73.0M$-98.0M$-51.0M$-37.0M
Net Profit$-76.0M$-65.0M$-82.0M$-44.0M$-14.0M
EPS$-23.04$-9.91$-8.63$-3.47$-1.09
Op Margin-442.7%-513.4%-485.3%-117.1%-377.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$126.0M$170.0M$161.0M$83.0M$42.0M
Total Liabilities$36.0M$68.0M$71.0M$31.0M$9.0M
Cash$66.0M$113.0M$117.0M$40.0M$37.0M
Borrowings$11.0M$7.0M$7.0M$1.0M$0

Latest News

Flexsteel Industries, Inc. (FLXS) Hits Fresh High: Is There Still Room to Run? Zacks · Jul 3, 2026 Hooker Furniture (HOFT) is on the Move, Here's Why the Trend Could be Sustainable Zacks · Jul 3, 2026 What Makes Hooker Furniture (HOFT) a Strong Momentum Stock: Buy Now? Zacks · Jul 1, 2026 Zacks.com featured highlights Vishay Precision, ASE Technology, StoneX, Hooker and Helios Zacks · Jun 24, 2026 Despite Fast-paced Momentum, Hooker Furniture (HOFT) Is Still a Bargain Stock Zacks · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-66.0M$-20.0M$-58.0M$-77.0M$-12.0M
Investing Cash Flow$-25.0M$-10.0M$-8.0M$0$7.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-76.0M$47.0M$4.0M$-78.0M$-2.0M
Free Cash Flow$-79.0M$-25.0M$-62.0M$-77.0M$-12.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA1.18
FCF Yield-49.33%
Quick Ratio3.93
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.13%
Institutions Held3.16%
Institutions Float Held3.17%
Institutional HolderSharesReport Date
Knoll Capital Management, LLC498,6252025-09-30
Xtx Topco Ltd18,0562025-09-30
Osaic Holdings Inc.5132025-09-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
ALEC $1.52 +0.33% -1.58 $168.20M 0.00%
DTIL $7.00 +1.60% -1.97 $89.80M 0.00%
GOSSGossamer Bio, Inc. $0.19 +38.24% -0.17 $44.10M 0.00%
KLDOKaleido Biosciences, Inc. $0.00 — 0.00 $426 0.00%

About HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

HOOKIPA Pharma Inc. is headquartered in US.

HOOKIPA Pharma Inc. (HOOK) stock trades at $1.15 with a market capitalization of $14.40M. The stock is valued at a price-to-earnings (P/E) ratio of -0.71, price-to-book of 0.51, price-to-sales of 1.64. Over the past 52 weeks the stock has ranged between $0.81 and $1.55, and currently trades 25.8% below its 52-week high.

On profitability, HOOKIPA Pharma Inc. generates a return on equity (ROE) of -54.85%, return on capital employed of -62.07%, an operating margin of -278.95%, a net profit margin of -195.62%.

Official website: www.hookipapharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides